MARCH/APRIL

Vol 9, No 2 CME Pretest

This Journal provides 4 hours of Category 1 Continuing Medical Education

Complimentary CME Credits

Physicians can earn 4 credit hours of Category 1 for the Physician's Recognition Award of the American Medical Association by reading the material in this issue and successfully answering the questions in the posttest at the end of this issue. Complete instructions are given on the posttest pages. Successfully answering 30 or more questions will earn 4 credit hours. CME is presented by an unrestricted educational grant from Bristol-Myers Squibb Oncology Division.

Educational Objectives

After reading this issue of Cancer Control, clinicians will be expected to:

• discuss the use of monoclonal antibodies with ABMT for non-Hodgkin’s lymphoma,

• recognize roles for radioimmunotherapy in NHL,

• describe the vaccines being developed and used in treating NHL,

• utilize donor lymphocyte transfusions after high-dose therapy, and

• understand new areas being studied for the treatment of hematologic malignancies.

This program was planned in accordance with ACCME Essentials.

Release Date: March1, 2002
Expiration Date: March 1, 2003

1. A policy of using rituximab as adjuvant therapy in the post–high-dose therapy/transplant setting for non-Hodgkin’s lymphoma may be associated with an increased risk of:

a. hepatic failure
b. graft-vs-host disease
c. graft failure
d. cytopenia and infections

2. Which of the following isotopes is a pure β-emitter?

a. yttrium-90 (⁹⁰Y)
b. bismuth-213 (²¹³Bi)
c. rhenium-188 (¹⁸⁸Re)
d. iodine-131 (¹³¹I)

3. When donor lymphocyte infusions are given to patients with relapsed myeloma, the dominant toxicity appears to be:

a. viral infections
b. graft-vs-host disease
c. hematologic suppression
d. respiratory failure